Abbott Laboratories $ABT Shares Bought by Acadian Asset Management LLC

Acadian Asset Management LLC grew its position in Abbott Laboratories (NYSE:ABT) by 82.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,896,714 shares of the healthcare product maker’s stock after buying an additional 1,309,523 shares during the quarter. Abbott Laboratories accounts for 0.8% of Acadian Asset Management LLC’s holdings, making the stock its 26th largest holding. Acadian Asset Management LLC owned approximately 0.17% of Abbott Laboratories worth $393,949,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ABT. Brighton Jones LLC lifted its holdings in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after buying an additional 4,755 shares in the last quarter. MJP Associates Inc. ADV increased its position in shares of Abbott Laboratories by 8.7% during the first quarter. MJP Associates Inc. ADV now owns 2,574 shares of the healthcare product maker’s stock worth $341,000 after acquiring an additional 207 shares during the period. IFC Advisors LLC raised its stake in shares of Abbott Laboratories by 3.0% in the first quarter. IFC Advisors LLC now owns 11,723 shares of the healthcare product maker’s stock valued at $1,555,000 after acquiring an additional 337 shares in the last quarter. Riversedge Advisors LLC boosted its holdings in Abbott Laboratories by 5.9% in the first quarter. Riversedge Advisors LLC now owns 3,657 shares of the healthcare product maker’s stock valued at $485,000 after purchasing an additional 204 shares during the period. Finally, Coyle Financial Counsel LLC grew its stake in Abbott Laboratories by 1.4% during the 1st quarter. Coyle Financial Counsel LLC now owns 5,972 shares of the healthcare product maker’s stock worth $792,000 after purchasing an additional 82 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ABT shares. Wells Fargo & Company increased their price target on Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a research report on Thursday, October 16th. Raymond James Financial raised their target price on shares of Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Jefferies Financial Group increased their price objective on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research report on Thursday, October 16th. Sanford C. Bernstein lifted their price objective on shares of Abbott Laboratories from $145.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. Finally, Benchmark initiated coverage on shares of Abbott Laboratories in a research note on Friday, October 10th. They set a “buy” rating and a $145.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $147.00.

Abbott Laboratories Stock Up 1.1%

Shares of NYSE:ABT opened at $126.28 on Friday. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The firm has a 50 day simple moving average of $130.78 and a 200-day simple moving average of $131.40. The company has a market capitalization of $219.59 billion, a PE ratio of 15.82, a P/E/G ratio of 2.36 and a beta of 0.68. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, hitting the consensus estimate of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The firm had revenue of $11.37 billion for the quarter, compared to analyst estimates of $11.40 billion. During the same period last year, the business earned $1.21 EPS. Abbott Laboratories’s revenue for the quarter was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.9%. Abbott Laboratories’s dividend payout ratio is 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.